Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TACR1 | P25103 | 9/20 | 0.55 |
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | CA4 | P22748 | 4/20 | 0.53 |
| ▸ | CA9 | Q16790 | 4/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | RHOC | P08134 | 1/20 | 0.45 |
| ▸ | RHOA | P61586 | 1/20 | 0.45 |
| ▸ | TACR3 | P29371 | 1/20 | 0.45 |
| ▸ | IDE | P14735 | 1/20 | 0.44 |
| ▸ | UBE2N | P61088 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7863763 | 1.00 | L3MBTL1 (0.56) | L3MBTL1TACR1CA1CA2CA4 | |
| SCHEMBL7462348 | 0.93 | L3MBTL1 (0.54) | L3MBTL1TACR1CA1CA2CA4 | |
| SCHEMBL7823087 | 0.92 | TACR1 (0.66) | L3MBTL1TACR1CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL7865340 | 0.91 | RHOC (0.53) | L3MBTL1TACR1CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL5366316 | 0.91 | RHOC (0.53) | L3MBTL1TACR1CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL8475576 | 0.91 | TACR1 (0.64) | L3MBTL1TACR1CA1CA2CA4 | |
| SCHEMBL5365341 | 0.90 | CA1 (0.47) | L3MBTL1TACR1CA1CA2CA4 | |
| SCHEMBL5363052 | 0.90 | L3MBTL1 (0.51) | L3MBTL1TACR1CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL6132629 | 0.89 | CA1 (0.48) | L3MBTL1TACR1CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL5379462 | 0.89 | CA1 (0.51) | L3MBTL1TACR1CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123532-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2007-05-31 | — | — | US | disclosed |
| US-7166598-B2 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases such as asthma, emesis, an anxiety disorder, pollakiuria, urinary incontinence and irritable bowel syndrome | ASTELLAS PHARMA INC. (JP) | 2007-01-23 | — | — | US | disclosed |
| EP-1140924-B1 | PIPERAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20060014948-A1 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-01-19 | — | — | US | disclosed |
| EP-0873320-B1 | PIPERAZINE DERIVATIVES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-06-12 | — | — | EP | disclosed |
| US-20020010182-A1 | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-24 | — | — | US | disclosed |
| EP-1140924-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| US-6087357-A | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| WO-2000035915-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014948-A1 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals | PKD2, TAC3, PKD1 | L3MBTL1 2649/4885TACR1 29/4885CA1 3146/4885 |
| US-20020010182-A1 | Piperazine derivatives as tachykinin antagonists | PKD2, SSTR5, TAC3 | L3MBTL1 4659/4885TACR1 5/4885CA1 2077/4885 |
| US-20070123532-A1 | PIPERAZINE DERIVATIVES | PKD2, SSTR5, IL5 | L3MBTL1 4833/4885TACR1 12/4885CA1 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.